Commonwealth Equity Services, LLC Ligand Pharmaceuticals Inc Transaction History

Commonwealth Equity Services, LLC

$68.4 Billion
Q4 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$94.99 - $151.56 $602,996 - $962,102	-6,348 Closed	0 $0
Q4 2021 Jan 31, 2022	BUY	$127.69 - $165.85 $613,678 - $797,075	4,806 Added 311.67%	6,348 $980,000
Q2 2021 Aug 11, 2021	SELL	$113.03 - $155.64 $3,277 - $4,513	-29 Reduced 1.85%	1,542 $202,000
Q1 2021 May 04, 2021	BUY	$99.52 - $215.83 $156,345 - $339,068	1,571 New	1,571 $239,000
Q4 2020 Feb 11, 2021	SELL	$80.55 - $106.05 $197,186 - $259,610	-2,448 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$89.56 - $126.72 $7,433 - $10,517	83 Added 3.51%	2,448 $233,000
Q2 2020 Aug 12, 2020	BUY	$68.28 - $123.65 $161,482 - $292,432	2,365 New	2,365 $264,000
Q1 2020 May 11, 2020	SELL	$63.37 - $107.88 $132,443 - $225,469	-2,090 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$96.94 - $113.59 $49,924 - $58,498	-515 Reduced 19.77%	2,090 $217,000
Q3 2019 Oct 30, 2019	SELL	$86.25 - $120.16 $207,517 - $289,104	-2,406 Reduced 48.01%	2,605 $259,000
Q2 2019 Jul 19, 2019	BUY	$107.38 - $129.34 $124,990 - $150,551	1,164 Added 30.26%	5,011 $572,000
Q1 2019 May 13, 2019	BUY	$105.93 - $142.47 $407,512 - $548,082	3,847 New	3,847 $483,000
Q4 2018 Feb 11, 2019	SELL	$128.36 - $272.13 $204,862 - $434,319	-1,596 Closed	0 $0
Q3 2018 Nov 06, 2018	BUY	$211.18 - $274.49 $115,726 - $150,420	548 Added 52.29%	1,596 $438,000
Q2 2018 Jul 31, 2018	SELL	$150.77 - $207.98 $24,273 - $33,484	-161 Reduced 13.32%	1,048 $217,000
Q1 2018 May 14, 2018	SELL	$138.63 - $182.62 $39,925 - $52,594	-288 Reduced 19.24%	1,209 $199,000
Q4 2017 Feb 12, 2018	BUY	$128.36 - $147.04 $192,154 - $220,118	1,497	1,497 $205,000

Others Institutions Holding LGND

# of Institutions

276

Shares Held

18.5M

Call Options Held

30.8K

Put Options Held

5.2K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.82B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account